Steward Partners Investment Advisory’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-113
| Closed | -$80 | – | 4324 |
|
|
2025
Q3 | $80 | Hold |
113
| – | – | ﹤0.01% | 4198 |
|
|
2025
Q2 | $127 | Hold |
113
| – | – | ﹤0.01% | 4036 |
|
|
2025
Q1 | $142 | Hold |
113
| – | – | ﹤0.01% | 3936 |
|
|
2024
Q4 | $257 | Sell |
113
-67
| -37% | -$124 | ﹤0.01% | 3894 |
|
|
2024
Q3 | $622 | Hold |
180
| – | – | ﹤0.01% | 3573 |
|
|
2024
Q2 | $914 | Sell |
180
-100
| -36% | -$750 | ﹤0.01% | 3405 |
|
|
2024
Q1 | $2.37K | Hold |
280
| – | – | ﹤0.01% | 3262 |
|
|
2023
Q4 | $1.15K | Sell |
280
-67
| -19% | -$201 | ﹤0.01% | 3292 |
|
|
2023
Q3 | $1.04K | Sell |
347
-200
| -37% | -$4.55K | ﹤0.01% | 3182 |
|
|
2023
Q2 | $16.9K | Hold |
547
| – | – | ﹤0.01% | 2368 |
|
|
2023
Q1 | $27.1K | Hold |
547
| – | – | ﹤0.01% | 2121 |
|
|
2022
Q4 | $13.4K | Hold |
547
| – | – | ﹤0.01% | 2432 |
|
|
2022
Q3 | $36K | Buy |
547
+100
| +22% | +$5.01K | ﹤0.01% | 1940 |
|
|
2022
Q2 | $18K | Sell |
447
-66
| -13% | -$2.97K | ﹤0.01% | 2266 |
|
|
2022
Q1 | $26K | Sell |
513
-134
| -21% | -$6.58K | ﹤0.01% | 2233 |
|
|
2021
Q4 | $39K | Sell |
647
-486
| -43% | -$23.9K | ﹤0.01% | 2022 |
|
|
2021
Q3 | $56K | Sell |
1,133
-134
| -11% | -$7.05K | ﹤0.01% | 1826 |
|
|
2021
Q2 | $72K | Sell |
1,267
-786
| -38% | -$42K | ﹤0.01% | 2696 |
|
|
2021
Q1 | $118K | Buy |
2,053
+1,033
| +101% | +$78K | ﹤0.01% | 1539 |
|
|
2020
Q4 | $69K | Sell |
1,020
-673
| -40% | -$91.7K | ﹤0.01% | 1513 |
|
|
2020
Q3 | $430K | Buy |
1,693
+40
| +2% | +$8.19K | 0.01% | 712 |
|
|
2020
Q2 | $278K | Buy |
1,653
+366
| +28% | +$39.5K | 0.01% | 781 |
|
|
2020
Q1 | $89K | Buy |
1,287
+1,054
| +452% | +$82.3K | ﹤0.01% | 1038 |
|
|
2019
Q4 | $14K | Buy |
233
+66
| +40% | +$3.83K | ﹤0.01% | 1884 |
|
|
2019
Q3 | $9K | Hold |
167
| – | – | ﹤0.01% | 2022 |
|
|
2019
Q2 | $9K | Buy |
+167
| New | +$9.72K | ﹤0.01% | 2009 |
|
|
2018
Q4 | – | Sell |
-400
| Closed | -$23K | – | 894 |
|
|
2018
Q3 | $23K | Buy |
+400
| New | +$24.2K | ﹤0.01% | 1489 |
|
|
2018
Q2 | – | Sell |
-200
| Closed | -$9K | – | 2451 |
|
|
2018
Q1 | $9K | Hold |
200
| – | – | ﹤0.01% | 1597 |
|
|
2017
Q4 | $11K | Buy |
+200
| New | +$12K | ﹤0.01% | 1317 |
|
Steward Partners Investment Advisory's BCLI Position: Q4 2025 in Review
Steward Partners Investment Advisory sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2025, closing a stake of 113 shares — an estimated $80 sold.
Steward Partners Investment Advisory first reported a position in BCLI in Q4 2017 and held it in 29 quarters. The position peaked at $430K in Q3 2020. 0 funds tracked by Wall St. Rank hold BCLI as of Q4 2025.
- Steward Partners Investment Advisory reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2025 after selling out during the quarter.
- Steward Partners Investment Advisory sold 113 BRAINSTORM CELL THERAPUTC shares in Q4 2025, an estimated $80.
- Steward Partners Investment Advisory first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2017 and held it in 29 quarters.
- Steward Partners Investment Advisory's BRAINSTORM CELL THERAPUTC position peaked at $430K in Q3 2020.
- 0 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2025.
Based on Steward Partners Investment Advisory's 13F filing for Q4 2025, filed 12 Feb 2026.